Calprotectin in the stool - Problems of determination (short communication)
Authors:
B. Friedecký
Published in:
Klin. Biochem. Metab., 34, 2026, No. 3, p. 0
Overview
The large number of methods used for very different analytical principles and on the other hand a very low level of standar - dization is the reason for extremely high differences in faecal calprotectine measurement. These differences are observed not only in external quality assessment programs, but in all published studies of comparability and validation. As opposed to this fact, the majority of publications and working sheets introduce very similar diagnostic decision limits values for this test. Several sophisticated publications on the guidance or consensus for measurement and results interpretation are for disposition, but their influence on the routine performances is negligible. We can say that the situation in measurement of analytes using the many possible methods, but minimal level of standardization is in sharp discrepancy with interoperability as a clear trend of contemporary laboratory medicine.
Keywords:
EQA – standardization – calprotectine – faeces – measurement methods – interoperability
Sources
1. Johnson, L. M., Spannagl, M., Wojtalewicz, N., Durner, J. Comparison of fecal calprotectin and pancreatic elastase assays based on proficiency testing results. Clin Biochem. 2022,107, 19-23. [odkaz]
2. National Institute for Health and Care Excellence. Faecal Calprotectin Diagnostic Tests fot Inflammatory Diseases of Bowel, 2013. [odkaz]
3. D‘Amico, F., Rubin, D.T., Kotze, P.G., Magro, F., Siegmund, B., Kobayashi, T., Olivera, P.A., Bossuyt, P., Pouillon, L., Louis, E., Domènech, E., Ghosh, S., Danese, S. and Peyrin-Biroulet, L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United. Eur. Gastroenterol J, 2021, 9, 451-460. [odkaz]
4. Manceau, H., Chicha-Cattoir, V., Puy, H., Peoc’h, K. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin. Chem. Lab. Med. (CCLM), 2017, 55(4), 474-483. [odkaz]
5. Whitehead, S. J., French, J., Brookes, M. J., Ford, C., Gama, R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann. Clin. Biochem. Int. J Lab. Med., 2013, 50(1), 53-61. [odkaz]
6. Juricic G, Brencic T, Tesija-Kuna A, Njegovan M, Honovic L. Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within - and between-method variability. Biochem. Med. (Zagreb), 2019, 29, 010707. [odkaz]
7. Pelkmans, L.P.J., de Groot, M.J.M., Curvers, J. Analytical Performance and Clinicopathologic Correlation of Four Fecal Calprotectin Methods. Am. J Clin. Pathol., 2019, 152(3), 392–398. [odkaz]
8. Kapel, N., Ouni, H., Benahmed, N. A., & Barbot-Trystram, L. Fecal Calprotectin for the Diagnosis and Management of Inflammatory Bowel Diseases. Clin. Translat. Gastroenterol., 2023,14(9), e00617. [odkaz]
9. Sciacovelli, L., Padoan, A., Aita, A., Basso, D., Plebani, M. Quality indicators in laboratory medicine: state-of-the-art, quality specifications and future strategies. Clin. Chem. Lab. Med. (CCLM), 2023, 61(4), 688-695. [odkaz]
10. Plebani, M. A value-based score for clinical laboratories: promoting the work of the new EFLM committee. Clin. Chem. Lab. Med. (CCLM), 2025, 63(8), 1481-1485. [odkaz]
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2026 Issue 3
Most read in this issue
- Glycated hemoglobin and alternative glycation biomarkers - a review from the perspective of laboratory medicine
- Jak se může změnit monitorování diabetu 2 typu v současnosti?
- Editorial: Glykovaný hemoglobin a jeho alternativy: rozšiřování možností, nikoli opuštění standardu
- Current status of POCT management in hospitals in the Czech Republic: findings from the POCT Forum 2026 workshop